Baseline ctDNA Shows Promise as Prognostic Biomarker in Follicular Lymphoma

Summary: Doctors have found a highly accurate way to predict how severe a type of blood cancer called follicular lymphoma will be before treatment even starts. By testing the blood for circulating tumor DNA (ctDNA), doctors can spot high-risk patients much better than they could using older clinical scoring charts. This simple blood test acts like a medical crystal ball, helping doctors personalize and intensify treatments early on for the patients who need it most.

Source: rssapp-oncologynurseadvisor-com URL: cancertherapyadvisor.com/news/ctdna-prognostic-biomarker-follicular-lymphoma/ (opens in new tab)